Review of TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis

The Institute was proposing that the consideration to review the existing guidance should be deferred until the completion of the SURPASS trial which is expected to be in 2013.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal. We will therefore defer the consideration to review the original guidance until 2013 when the results of ongoing trials are available. At this point the evidence base will again be assessed to ascertain the need for a review of the current guidance.

December 2010